Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?

European Journal of Cancer

Volumn 36, Issue 2, 2000, Pages 200-206

  Maisey, N R ^a   Hill, M E ^a   Webb, A ^a   Cunningham, D ^a   Flux, G D ^a   Padhani, A ^a   Ott, R J ^a   Norman, A ^a   Bishop, L ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Fluorodeoxy F 18; Hodgkin's disease; Magnetic resonance imaging; Non Hodgkin's lymphoma; Positron emission tomography; Residual disease

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; DIAGNOSTIC VALUE; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FOLLOW UP; HODGKIN DISEASE; METHODOLOGY; MIDDLE AGED; NONHODGKIN LYMPHOMA; RECURRENT DISEASE; SCINTISCANNING;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; RECURRENCE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033621989     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00249-X     Document Type: Article

References (30)

1. Surbonn A., Longo D.L., DeVita V.T. Jr.et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy. significance and management. J. Clin. Oncol. 6:1988;1832-1837.
2. Foote G., Matthews J. Residual abdominal masses following treatment of Hodgkin's disease. Australas. Radiol. 24:1980;151-155.
3. Katz M., Piekarski J., Bayle-Weisgerber C., Laval-Jeantet M., Teillet F. Masses mediastinales residuelles post-radiotherapiques au cours de la maladie de Hodgkin. Ann. Radiol. 20:1977;667-672.
4. Chen J., Osborne B., Butler J. Residual fibrous masses in treated Hodgkin's disease. Cancer. 60:1987;407-413.
5. Jochelson M., Mauch P., Balikian J., Rosenthal D., Canellos G. The significance of the residual mediastinal mass in treated Hodgkin's disease. J. Clin. Oncol. 3:1985;637-640.
6. Radford J.A., Cowan R.A., Flanagan M.et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J. Clin. Oncol. 6:1988;940-946.
7. Loeffler M., Brosteanu O., Hasenclever D.et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J. Clin. Oncol. 16:1998;818-829.
8. Aviles A., Delgado S., Nambo M.J., Alatriste S., Diaz-Maqueo X. Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 30:1994;799-803.
9. Gustavsson A., Eskilsson J., Lanberg T.et al. Late cardiac effects of mantle radiotherapy in patients with Hodgkin's disease. Ann. Oncol. 1:1990;355-363.
10. Morgan G., Freeman A., McKlean R.et al. Late cardiac, thyroid and pulmonary sequelae of mantle radiotherapy for Hodgkin's disease. Int. J. Radiat. Oncol. Biol. Phys. 11:1985;1925-1931.
11. Van Leeuwan F., Klokman W., Hagenbeek A.et al. Second cancer risk following Hodgkin's disease: a twenty year follow-up study. J. Clin. Oncol. 12:1994;312-325.
12. Hagemeister F., Fesum S., Larriki L., Haynie T. Role of the gallium scan in Hodgkin's disease. Cancer. 65:1990;1090-1096.
13. Henry-Amar M., Friedman S., Hayat M.et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin's disease. Ann. Intern. Med. 114:1991;361-365.
14. Hill M., Cunningham D., MacVicar D.et al. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J. Clin. Oncol. 11:1993;2273-2278.
15. Warburg O. On the origin of cancer cells. Science. 123:1956;309-314.
16. Hoh C.K., Schiepers C., Seltzer M.A.et al. PET in oncology: will it replace the other modalities? Semin. Nucl. Med. 27:1997;94-106.
17. Rahmouni A., Tempany C., Jones R., Mann R., Yang A., Zerhouni E. Lymphoma: monitoring tumor size and signal intensity with MR imaging. Radiology. 188:1993;445-451.
18. Marsden P.K., Ott R.J., Bateman J.E., Cherry S.R., Flower M.A., Webb S. The performance of a multiwire proportional chamber positron camera for clinical use. Phys. Med. Biol. 34:1989;1043-1062.
19. Miller A.B., Hoogstraten M.D., Staquet M., Winkler M.D. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
20. Altman D.G. Practical Statistics for Medical Research. 1991;Chapman & Hall, London.
21. Meyer M.A. Diffusely increased colonic F-18 FDG uptake in acute enterocolitis. Clin. Nucl. Med. 20:1995;434-435.
22. Kubota R., Kubota K., Yamada S., Tada M., Ido T., Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J. Nucl. Med. 35:1994;104-112.
23. Haberkorn U., Strauss L.G., Dimitrakopoulou A.et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J. Nucl. Med. 32:1991;1485-1490.
24. Engenhart R., Kimmig B.N., Strauss L.G.et al. Therapy monitoring of presacral recurrences after high-dose irradiation. value of PET, CT, CEA and pain score Strahlenther. Onkol. 168:1992;203-212.
25. Haberkorn U., Reinhardt M., Strauss L.G.et al. Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy. J. Nucl. Med. 33(11):1992;1981-1987.
26. Minn H., Kangas L., Kellokumpu Lehtinen P.et al. Uptake of 2-fluoro-2deoxy-D-[U-14C]-glucose during chemotherapy in murine Lewis lung tumor. Int. J. Rad. Appl. Instrum. B. 19:1992;55-63.
27. Strauss L.G. Fluorine-18 deoxyglucose and false-positive results. a major problem in the diagnostics of oncological patients Eur. J. Nucl. Med. 23:1996;1409-1415.
28. Lapela M., Leskinen S., Minn H.R.et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood. 86:1995;3522-3527.
29. de Wit M., Bumann D., Beyer W., Herbst K., Clausen M., Hossfeld D.K. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann. Oncol. 8:1997;57-60.
30. Bangerter M., Moog F., Griesshammer M., Reske S.N., Bergman L. Role of whole body FDG-PET in predicting relapse in residual masses after treatment of lymphoma. Br. J. Haematol. 102:1998;148.